3 news items
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
RVNC
9 May 24
, I'm excited to offer my patients a new therapy that offers sustained symptom control."
For more
Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
patients, in order to provide sustained symptom control and reduce the symptom rollercoaster experienced by a vast number of those suffering
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
of individual patients, in order to provide sustained symptom control and reduce the symptom rollercoaster experienced by a vast number of those suffering
- Prev
- 1
- Next